149 results
Page 7 of 8
425
EX-10.1
7uoyl5h93n7g 2a
1 Apr 08
Business combination disclosure
12:00am
6-K
bxxkg
23 Oct 07
Copaxone? Significantly Decreases Disease Activity In Patients Who Switched from Interferon Beta (Ifnb) Due to Development of Neutralizing Antibodies (Nabs)
12:00am
6-K
ccrbcgpvyzoiz1suky
15 Oct 07
Long-term Study Shows Copaxone? Significantly Slows Progression of Disability and Reduces Relapse Rates In Patients with Relapsing-remitting Multiple Sclerosis
12:00am
6-K
55yrh9gleiuom1da
13 Jun 07
Current report (foreign)
12:00am
6-K
ml169ukcnw7i
7 Jun 07
Teva and Active Biotech to Initiate Pivotal Phase III Trial Program of Oral Laquinimod for Relapsing Multiple Sclerosis
12:00am
6-K
w5t 4wvsspbpsndt
2 May 07
Laquinimod, a Novel Oral Compound, Showed Significant Reduction In Disease Activity In Patients with Relapsing- Remitting Multiple Sclerosis (RRMS)
12:00am
6-K
lq3wugj4 bhcrt78vlaf
17 Apr 07
Data Published In Neurology Showed That Higher Dose of Copaxone? Increased Efficacy In Relapsing-remitting Multiple Sclerosis (RRMS)
12:00am
6-K
ll8rlpf
5 Sep 06
Laquinimod Phase Iib Trial Confirms Efficacy and Favorable Safety Profile and Shows Significant Reduction In the Rate of Inflammatory Disease Activity
12:00am
6-K
t0vfwtsnbwdjypmew8et
27 Jul 06
Teva Initiates Phase III Study to Confirm Increased Efficacy of Higher Dose of Glatiramer Acetate for the Treatment of Relapsing-remitting Multiple Sclerosis
12:00am
6-K
jt7ezbcovkw jlap1g26
6 Apr 06
Teva Announces That Higher Dose of Copaxone? Showed Increased Efficacy In Multiple Sclerosis (MS)
12:00am
6-K
9ehvzu3
6 Apr 06
Notice of Annual Meeting of Shareholders - Amendment
12:00am
6-K
5hk9oi5
3 Apr 06
Proxy Statement
12:00am
6-K
EX-4.2
oth52webxh3no
31 Jan 06
Current report (foreign)
12:00am
6-K
EX-4.5
0pep9g7i td
31 Jan 06
Current report (foreign)
12:00am
F-4
EX-99.2
d674y45 pzhpmn4uey8
2 Sep 05
Registration of securities (foreign)
12:00am